ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lifted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 77.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,169 shares of the biopharmaceutical company's stock after acquiring an additional 30,232 shares during the period. Schonfeld Strategic Advisors LLC's holdings in ACADIA Pharmaceuticals were worth $1,269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Barclays PLC boosted its holdings in shares of ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after purchasing an additional 154,854 shares during the last quarter. Nordea Investment Management AB grew its position in ACADIA Pharmaceuticals by 1.3% in the fourth quarter. Nordea Investment Management AB now owns 264,031 shares of the biopharmaceutical company's stock worth $4,952,000 after acquiring an additional 3,516 shares during the period. Diversified Trust Co lifted its position in ACADIA Pharmaceuticals by 9.8% in the fourth quarter. Diversified Trust Co now owns 35,774 shares of the biopharmaceutical company's stock valued at $656,000 after buying an additional 3,187 shares during the last quarter. Burney Co. purchased a new position in ACADIA Pharmaceuticals during the fourth quarter worth about $6,953,000. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of ACADIA Pharmaceuticals by 7.8% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 103,325 shares of the biopharmaceutical company's stock valued at $1,896,000 after acquiring an additional 7,491 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ACAD shares. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, March 8th. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 8th. Morgan Stanley reiterated an "equal weight" rating and set a $20.00 price target on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $24.21.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 3,498 shares of the company's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $14.60, for a total value of $51,070.80. Following the completion of the sale, the executive vice president now directly owns 62,773 shares of the company's stock, valued at $916,485.80. This represents a 5.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now directly owns 17,595 shares in the company, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,994 shares of company stock valued at $313,131 in the last ninety days. Insiders own 26.50% of the company's stock.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD opened at $14.79 on Thursday. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $20.68. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 18.96 and a beta of 0.47. The business has a 50-day moving average of $15.87 and a two-hundred day moving average of $16.91.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. During the same period in the prior year, the company posted $0.10 earnings per share. The firm's quarterly revenue was up 18.7% compared to the same quarter last year. As a group, equities research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.